What happened
Par Health announced on October 13 a nationwide recall of 22 lots of Argatroban Injection, 250 mg/2.5 mL, to the hospital/user level. FDA posted the company’s announcement on October 14. Testing found particulate material in certain lots, including cellulose, plastics and stopper material, with possible stainless steel. Argatroban is an injectable anticoagulant used in specified adults with heparin-induced thrombocytopenia.
Why it matters
Unlike a medicine taken by another route, an injectable product can introduce particulate material into the bloodstream. That makes the manufacturer’s contamination finding actionable even though it reported no related adverse events at the time. The practical response is specific: facilities holding the recalled lots are instructed to stop using and distributing them immediately, rather than treating the notice as a conclusion about all argatroban.
Evidence
In its FDA-posted announcement, the manufacturer says injecting contaminated product has a reasonable probability of causing life-threatening consequences, including blockages in lung or other blood vessels. It also says it had received no adverse-event reports related to the recall at the time of the announcement. That absence of reports does not change the stated potential severity of the hazard.
The affected lots carry NDC 42023-182-01 or 42023-182-89 and were distributed to wholesalers and hospitals between December 30, 2024, and May 5, 2026. Par Health instructs wholesalers and hospital pharmacies with recalled product to discontinue its use and distribution immediately, notify downstream accounts where applicable, and arrange returns. The recall concerns the identified lots, not every argatroban product. FDA states that it posts company recall announcements as a public service and does not endorse the company or product. (fda.gov)
What remains unknown
The announcement does not say how many affected vials remain in circulation or establish that any patient has been injured. Those unknowns limit conclusions about actual exposure; they do not reduce the importance of identifying and removing the listed lots.
Who may be affected
Wholesalers, hospital pharmacies and clinical teams holding the listed NDCs and lot numbers, and patients who could otherwise receive an affected vial.
AXIONOVA connection
This is an immediate, lot-specific product-quality alert. The information to monitor next is any FDA or manufacturer update to the affected lots, distribution or reported adverse events; none is needed before facilities holding recalled product follow the stop-use instruction.
What ALETHA can explain
ALETHA can explain how an NDC and lot number help identify affected product, why an urgent recall need not await an injury report, and why an announcement hosted by FDA remains the manufacturer’s hazard assessment.
Action posture
Urgent official safety direction: The FDA-posted recall contains an applicable immediate stop-use and stop-distribution instruction for facilities holding the specified lots.